Cargando…
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
Patients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) and patients whose minimal residual disease persists during treatment have a poor leukemia-free survival. Despite improvements in front-line therapy, the outcome in these patients remains poor, especially after re...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762579/ https://www.ncbi.nlm.nih.gov/pubmed/26937176 http://dx.doi.org/10.2147/DDDT.S83848 |